The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Dupilumab and tralokinumab treat atopic dermatitis ... You give it to yourself as an injection under the skin every other week or once a month. Your doctor will prescribe either a prefilled ...

randomized to 300 mg of subcutaneous dupilumab or a placebo injection every 2 weeks. At 36 weeks, 20% of those treated with dupilumab achieved the primary endpoint of sustained disease remission ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi ... Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your ...

At that time Sanofi was cruising towards an important FDA approval for its Dupixent (dupilumab) injection for the skin disease also known as atopic dermatitis. Noting the blockbuster potential for ...

for Dupixent ® (dupilumab) to treat adults with bullous pemphigoid (BP). The sBLA is supported by data from a pivotal trial evaluating the efficacy and safety of Dupixent in 106 adults with ...

Perspective from John Luo, MD Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was able to improve lichenification among patients aged 6 to 88 years with atopic dermatitis.

and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent ® (dupilumab) in adults with moderate-to-severe bullous ...